Prof. Serge GOLDMAN, Ph. D., ULB, Erasme Hospital
Serge Goldman was born in 1957 and he studied at the Medical School of the Université Libre de Bruxelles. He is MD with successive certifications in neurology and in nuclear medicine and with a thesis leading to the “agrégation de l’enseignement supérieur” in Medical Science. He is head of the Department of Nuclear Medicine and the PET/Biomedical Cyclotron Unit at ULB - Erasme Hospital since 2002. He got trained in PET imaging during a fellowship at Johns Hopkins University in the research group of Pr. H.N. Wagner. He has published 185 full articles and a dozen of book chapters during the last 25 years. Most of his scientific production relates to PET imaging, including for animal models. His main field of research is imaging of brain tumors with a particular stress put on the integration of molecular imaging in therapy targeting. Other fields of interest are imaging for cell tracking and neurological applications of PET, in particular in the domains of neurodegeneration, epilepsy and development. He has been President of the Belgian Society of Nuclear Medicine from 2007 to 2010.
Gilles DOUMONT, Ph. D.
Gilles Doumont got his Master in Chemistry in 1999 at the Université Libre de Bruxelles (ULB). He then started a PhD in Molecular Biology in the IBMM-ULB, and graduated in 2005. Oncology constituted his area of interest. In particular he focused on the study of two new mediators of the biological activity of the tumour suppressor p53. To extend his area of competencies in Oncology he started to work as postdoctoral researcher in NKI-AVL, Amsterdam, The Netherlands, an institute entirely dedicated to cancer research. The aim of his research was to identify new critical molecules involved in metastasis development using a mouse model for invasive lobular carcinoma, one of the most invasive breast cancers affecting women. He had the financial support of the European Molecular Biology Organization (EMBO long term fellowship). Back in Belgium in April 2011 Gilles Doumont is working as a researcher at the CMMI.
Nuclear molecular imaging - in vivo
- NanoPET/CT (Bioscan, USA)
- NanoSPECT (Bioscan, USA)
- Buffin A, Denis D, Van Simaeys G, Goldman S and Deneubourg J L. Feeding and stocking up: radio-labelled food reveals exchange patterns in ants. PLoS One 4: e5919. 2009.
- Dedobbeleer C, Blocklet D, Toungouz M, Lambermont M, Unger P, Degaute J P, Goldman S and Berkenboom G. Myocardial homing and coronary endothelial function after autologous blood CD34+ progenitor cells intracoronary injection in the chronic phase of myocardial infarction. J Cardiovasc Pharmacol 53: 480-5. 2009.
- Flamez D, Roland I, Berton A, Kutlu B, Dufrane D, Beckers M C, De Waele E, Rooman I, Bouwens L, Clark A, Lonneux M, Jamar J F, Goldman S, Marechal D, Goodman N, Gianello P, Van Huffel C, Salmon Iand Eizirik D L. A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)gammaa as a pancreatic beta cell-specific biomarker. Diabetologia 53: 1372-83. 2010.
- Bouckenooghe T, Flamez D, Ortis F, Goldman S and Eizirik D L. Identification of new pancreatic Beta cell targets for in vivo imaging by a systems biology approach. Curr Pharm Des 16: 1609-18. 2010.
- M. de Heusch , D. Blocklet, D. Egrise, B. Hauquier, M. Vermeersch, S. Goldman, and M. Moser, Bidirectional MHC molecule exchange between migratory and resident dendritic cells ; J Leukoc Biol 82, pp 861-8 (2007).
- P. Van Bogaert, X. De Tiege, J.M. Vanderwinden, P. Damhaut, S. N. Schiffmann, and S. Goldman, Comparative study of hippocampal neuronal loss and in vivo binding of 5-HT1a receptors in the KA model of limbic epilepsy in the rat ; Epilepsy Research 47, pp 127-39 (2001).
- M. Monclus, A. Luxen, V. Cool, P. Damhaut, T. Velu, and S. Goldman, Development of a positron emission tomography radiopharmaceutical for imaging thymidine kinase gene expression: synthesis and in vitro evaluation of 9-[(3-[18F]fl uoro-1-hydroxy-2-propoxy)methyl] guanine ; Bioorg Med Chem Lett 7, pp 1879-1882 (1997).
- T. Pauwels, S. Dethy, S. Goldman, M. Monclus, and A. Luxen, Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F] fl uoro-L-dopa ; Eur J Pharmacol 257, pp 53-8 (1994).
Description and applications
The nuMIx lab is specialized in preclinical nuclear imaging in vivo and ex vivo. nuMix is proposing services in in vivo preclinical nuclear imaging by PET, SPECT and CT using last generation cameras (Bioscan, USA).
Nuclear Molecular Imaging relies on the detection of γ photons emitted by radioactive labels, i.e., radiotracers. These radiotracers are selected molecules typical for specific metabolic pathways that are made visible to the detection system after labelling with some appropriate radionuclide. This imaging technique delivers images depicting the radiotracer distribution, which reflects the function or metabolic activity of organs, tissues or tumours.
Positron Emission Tomography (PET) requires short half-life radionuclides usually produced in a cyclotron ; a PET camera generates essentially 3D quantitative images with extremely high sensitivity (< pM).
Single Photon Emission Computed Tomography (SPECT) is based on radiotracers different than those used in PET, usually with a longer half-life, which allows to carry out follow-up imaging studies. Spatial resolution of these images is similar to that of PET, and is in the order of mm, however, the sensitivity of this method is noticeably lower. Nevertheless, SPECT allows imaging of different radiotracers simultaneously.
X-ray Computed Tomography (X-CT) yields structural/anatomical highresolution 3D images based on the differential attenuation of X-rays in biological tissues. This imaging modality complements the metabolic or functional images obtained with PET or SPECT.
See the poster: POSTER_CMMI_-_nuMix.pdf